Som med andre HMG- CoA reduktasehæmmere kan initiering af behandling eller dosis optitrering med Crestor hos patienter som samtidig behandles med vitamin K antagonister (f. eks. warfarin) resultere i en stigning i International Normaliseret Ratio (INR).
As with other HMG-CoA reductase inhibitors, the initiation of treatment or dosage up-titration of Crestor in patients treated concomitantly with vitamin K antagonists (e. g. warfarin) may result in an increase in International Normalised Ratio (INR).